Home Alzheimer’s Disease Lenvatinib/Everolimus Combo May Be Acceptable After Immunotherapy in Clear Cell RCC

Lenvatinib/Everolimus Combo May Be Acceptable After Immunotherapy in Clear Cell RCC

The combination of lenvatinib (Lenvima) plus everolimus was found to be safe and effective in patients with clear cell renal cell carcinoma (RCC) who had been treated with an immune checkpoint inhibitor in prior lines of therapy.1

These results were from an exploratory analysis of a phase 2 trial (NCT03173560) of lenvatinib at 2 different starting doses plus a set dose of everolimus following prior VEGF inhibitor therapy and were presented virtually at the 2021 Genitourinary Cancers Symposium.

“Because of changes to the treatment landscape, first-line treatment often includes immune checkpoint inhibitor (ICI) therapy, and therefore, it is important to examine the antitumor response and safety of lenvatinib [plus] everolimus in this patient subgroup,” the study investigators, who were led by Sumanta K. Pal, MD, wrote in their poster presentation.

Out of 343 patients enrolled in the…

Continue Reading to the Source


Please enter your comment!
Please enter your name here

Most Popular

Lower-Dose Hypofractionated Radiotherapy Schedule Proves Effective for Patients With Locally Advanced Bladder Cancer

Using a hypofractionated schedule of 55 Gy in 20 fractions over 4 weeks to treat patients with locally advanced bladder cancer was noninferior to...

Study Identifies New Biomarker Which Could Predict Response to CD40 Immunotherapy in Pancreatic Cancer

Research published in JCI Insight identified systemic inflammation as a possible resistance mechanism to a CD40–based chemoimmunotherapy in patients with advanced pancreatic cancer.1According to...

Significant Interfacility Variation Found in Implementation of Low-Value Breast Cancer Procedures

A number of facility-level characteristics were associated with the use of low-value breast cancer procedures, and interfacility variation presented an opportunity for formal de-implementation...

KarMMa Trial Results for Ide-Cel in Refractory Myeloma Show Favorable Efficacy

Chimeric antigen receptor (CAR) T-cell therapy with idecabtagene vicleucel (ide-cel) induced responses in almost 75% of patients with multiple myeloma following relpase on multiple...

Recent Comments